0001209191-21-039632.txt : 20210610
0001209191-21-039632.hdr.sgml : 20210610
20210610185504
ACCESSION NUMBER: 0001209191-21-039632
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210608
FILED AS OF DATE: 20210610
DATE AS OF CHANGE: 20210610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELMS STEVE
CENTRAL INDEX KEY: 0001250195
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37939
FILM NUMBER: 211009442
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 29TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Marker Therapeutics, Inc.
CENTRAL INDEX KEY: 0001094038
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 880277072
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3200 SOUTHWEST FREEWAY
STREET 2: SUITE 2500
CITY: HOUSTON
STATE: TX
ZIP: 77027
BUSINESS PHONE: (713) 400-6400
MAIL ADDRESS:
STREET 1: 3200 SOUTHWEST FREEWAY
STREET 2: SUITE 2500
CITY: HOUSTON
STATE: TX
ZIP: 77027
FORMER COMPANY:
FORMER CONFORMED NAME: TAPIMMUNE INC.
DATE OF NAME CHANGE: 20170629
FORMER COMPANY:
FORMER CONFORMED NAME: TAPIMMUNE INC
DATE OF NAME CHANGE: 20070628
FORMER COMPANY:
FORMER CONFORMED NAME: GENEMAX CORP
DATE OF NAME CHANGE: 20020718
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-08
0
0001094038
Marker Therapeutics, Inc.
MRKR
0001250195
ELMS STEVE
C/O MARKER THERAPEUTICS, INC.
3200 SOUTHWEST FREEWAY, SUITE 2500
HOUSTON
TX
77027
1
0
0
0
Common Stock
2021-06-08
4
A
0
12658
0.00
A
29680
D
Common Stock
3142857
I
See footnote
Represents the portion of the annual board retainer for each non-employee director payable in immediately vested common stock under the Company's 2020 Equity Incentive Plan and based on the closing price of $3.16 per share, on the day immediately preceding the date of the Company's 2021 annual meeting.
The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.
/s/ Michael Loiacono, Attorney-in-Fact
2021-06-10